Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401
Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...
Cancer
Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...
Sichuan Biokin Pharmaceutical Gets NMPA Approval for BL-M14D1 Clinical Trial in Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...
KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market
Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...
Allist Pharmaceuticals Faces Arbitration Over Promotion Agreement for Furmonertinib
Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received a...
Amgen Halts Development of Claudin 6-Targeting BiTE Immune Therapy AMG 794
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has decided to...
Shanghai Junshi Biosciences’ HDAC Inhibitor JS125 Clinical Trial Application Accepted by NMPA
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
GRIT Biotechnology and Quangang Pharmaceutical Co., Ltd Partner to Develop TIL and IL-2 Combination Therapy
GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic...
Shandong Buchang Pharmaceuticals Receives NMPA Approval for BC008-1A Biologic Product Clinical Trial
Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a pharmaceutical company based in China, has announced...
Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...
Hinova Pharmaceuticals’ HP537 Receives FDA Approval for Phase I/II Clinical Trial in Hematologic Malignancies
Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...
Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted
Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...
Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a
Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...
J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients
Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...
CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a...